- Home
- YOSH vs CTXR Comparison
YOSH vs CTXR Comparison
Compare YOSH & CTXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YOSH
- CTXR
- Stock Information
- Founded
- YOSH 2016
- CTXR 2007
- Country
- YOSH United States
- CTXR United States
- Employees
- YOSH N/A
- CTXR N/A
- Industry
- YOSH Restaurants
- CTXR Biotechnology: Pharmaceutical Preparations
- Sector
- YOSH Consumer Discretionary
- CTXR Health Care
- Exchange
- YOSH Nasdaq
- CTXR Nasdaq
- Market Cap
- YOSH 23.7M
- CTXR 20.8M
- IPO Year
- YOSH 2022
- CTXR N/A
- Fundamental
- Price
- YOSH $1.71
- CTXR $1.23
- Analyst Decision
- YOSH
- CTXR Strong Buy
- Analyst Count
- YOSH 0
- CTXR 3
- Target Price
- YOSH N/A
- CTXR $53.00
- AVG Volume (30 Days)
- YOSH 204.9K
- CTXR 479.9K
- Earning Date
- YOSH 08-20-2025
- CTXR 08-12-2025
- Dividend Yield
- YOSH N/A
- CTXR N/A
- EPS Growth
- YOSH N/A
- CTXR N/A
- EPS
- YOSH N/A
- CTXR N/A
- Revenue
- YOSH $13,902,861.00
- CTXR N/A
- Revenue This Year
- YOSH N/A
- CTXR N/A
- Revenue Next Year
- YOSH N/A
- CTXR $851.67
- P/E Ratio
- YOSH N/A
- CTXR N/A
- Revenue Growth
- YOSH 30.39
- CTXR N/A
- 52 Week Low
- YOSH $0.68
- CTXR $0.65
- 52 Week High
- YOSH $5.63
- CTXR $15.25
- Technical
- Relative Strength Index (RSI)
- YOSH 39.12
- CTXR 44.57
- Support Level
- YOSH $1.22
- CTXR $1.10
- Resistance Level
- YOSH $1.95
- CTXR $1.57
- Average True Range (ATR)
- YOSH 0.16
- CTXR 0.11
- MACD
- YOSH 0.01
- CTXR -0.01
- Stochastic Oscillator
- YOSH 13.70
- CTXR 26.49
About YOSH Yoshiharu Global Co.
Yoshiharu Global Co is a restaurant operator. The company has one reportable segment, consisting of operating its stores. Yoshiharu serves the perfect, ideal ramen, as well as offers customers a wide variety of sushi, bento menus, and other favorite Japanese cuisines. It owns and operates restaurant stores.
About CTXR Citius Pharmaceuticals Inc.
Citius Pharmaceuticals Inc is a biopharmaceutical company with a focus on anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. The company is currently advancing four proprietary product candidates namely, LYMPHIR for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Mino-Lok, which is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections, Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries, Halo-Lido, a topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids, and others.